基本信息:
- 专利标题: Influence caused by midkine when endometriosis appear
- 专利标题(中):当子宫内膜炎引起的中风引起的影响
- 申请号:JP2004236085 申请日:2004-08-13
- 公开(公告)号:JP2007297282A 公开(公告)日:2007-11-15
- 发明人: OSUGA MINORU , HIROTA YASUSHI , SAKUMA SADATOSHI
- 申请人: Cell Signals Inc , 株式会社セルシグナルズ
- 专利权人: Cell Signals Inc,株式会社セルシグナルズ
- 当前专利权人: Cell Signals Inc,株式会社セルシグナルズ
- 优先权: JP2004236085 2004-08-13
- 主分类号: A61K45/00
- IPC分类号: A61K45/00 ; A61K31/7088 ; A61K31/7105 ; A61K39/395 ; A61K48/00 ; A61P15/00 ; C12N15/09 ; C12Q1/68 ; G01N33/53
摘要:
PROBLEM TO BE SOLVED: To provide an agent, used for preventing or treating endometriosis, targeting midkine (MK) and to provide a method for examining endometriosis and to provide an examination medicine. SOLUTION: By studying the mitogen activity of MK on cultured endometrial stromal cells, it is clarified that MK stimulates the proliferation of ESC. By evaluating the MK concentration in the peritoneal fluid (PF), it is clarified that the MK level is elevated in a female with the progress of endometriosis. It is further found out that the MK concentration in the PF of a female under the therapy with GnRH agonist is significantly lower than the concentration in another group. It is indicated that MK mRNA is expressed in cells originating in peritoneal bone marrow, the peritoneal membrane and an intrauterine tissue. COPYRIGHT: (C)2008,JPO&INPIT
摘要(中):
要解决的问题:提供用于预防或治疗子宫内膜异位症的药物,靶向中期因子(MK),并提供检查子宫内膜异位症和提供检查药物的方法。 解决方案:通过研究MK对培养的子宫内膜基质细胞的丝裂原活性,阐明了MK刺激ESC的增殖。 通过评估腹膜液(PF)中的MK浓度,阐明了随着子宫内膜异位症进展,MK水平升高。 进一步发现,用GnRH激动剂治疗的女性PF中的MK浓度显着低于另一组中的浓度。 表明MK mRNA在源自腹膜骨髓,腹膜和子宫内组织的细胞中表达。 版权所有(C)2008,JPO&INPIT
信息查询:
EspacenetIPC结构图谱:
A | 人类生活必需 |
--A61 | 医学或兽医学;卫生学 |
----A61K | 医用、牙科用或梳妆用的配制品 |
------A61K45/00 | 在A61K31/00至A61K41/00各组中不包含的含有效成分的医用配制品 |